Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
INR2,483.70
+20.30 (+0.82%)
IN NSE Healthcare Drug Manufacturers - General
Address
GSK House 400030
Mumbai, IN
Mumbai, IN
CEO
Bhushan Akshikar
Website
india-pharma.gsk.com
IPO
2002-07-01
ISIN INE159A01016
Also trades on
Bombay Stock Exchange · GLAXO.BO (INR)
National Stock Exchange of India · GLAXO.NS (INR)
Description
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
INR2,483.70
+20.30 (+0.82%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
107.7K
Beta
0.05
Float Shares
41.25M
Free Float %
24.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.21% | -2.60% | +0.48% | -6.85% | -2.53% | -2.30% | -16.05% | +88.81% | +60.67% | +40.69% | +685.92% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2,483.70
DCF (Unlevered)
4,984.58
+100.7%
DCF (Levered)
5,210.89
+109.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
75% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 2 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
14.38
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - General: +6.6%+2.6% Q1'26: +4.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - General: +18.2%+11.7% Q1'26: +5.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%+20.5% Q1'26: +16.7% (vs Q1'25)
-
EBIT margin Drug Manufacturers - General: +19.4%+32.5% ★ Q1'26: +33.9% (vs Q1'25)
-
ROIC Drug Manufacturers - General: +10.2%— Q1'26: -209.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - General: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×0.03× ★ Q1'26: 0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 4 Rev. Ana. 4 EPS Ana. |
Mar 2027 1 Rev. Ana. 4 EPS Ana. |
Mar 2028 3 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
26.38B
est: 27.41B (-3.8%)
|
26.84B
est: 28.26B (-5.0%)
|
29.08B
est: 29.26B (-0.6%)
|
28.06B
est: 30.12B (-6.8%)
|
30.99B
est: 32.50B (-4.7%)
|
31.99B
est: 32.75B (-2.3%)
|
28.99B
est: 32.59B (-11.0%)
|
32.64B
est: 34.31B (-4.9%)
|
32.26B
est: 33.06B (-2.4%)
|
34.42B
est: 33.59B (+2.5%)
|
37.26B
est: 37.58B (-0.8%)
|
38.47B
38.09B – 38.83B
+2.4% YoY
|
42.21B
41.97B – 42.40B
+9.7% YoY
|
46.67B
46.17B – 47.08B
+10.6% YoY
|
| EBITDA |
5.09B
est: 6.73B (-24.4%)
|
6.04B
est: 8.32B (-27.4%)
|
5.37B
est: 7.61B (-29.4%)
|
5.78B
est: 6.37B (-9.3%)
|
7.32B
est: 6.61B (+10.6%)
|
3.94B
est: 7.97B (-50.6%)
|
5.36B
est: 4.25B (+26.2%)
|
8.49B
est: 4.72B (+79.7%)
|
9.04B
est: 4.98B (+81.5%)
|
8.88B
est: 8.25B (+7.6%)
|
13.28B
est: 10.07B (+31.9%)
|
10.31B
10.20B – 10.40B
+2.4% YoY
|
11.31B
11.24B – 11.36B
+9.7% YoY
|
12.50B
12.37B – 12.61B
+10.6% YoY
|
| EBIT |
4.89B
est: 6.37B (-23.3%)
|
5.79B
est: 4.75B (+21.8%)
|
5.11B
est: 4.62B (+10.7%)
|
5.40B
est: 4.15B (+30.1%)
|
6.83B
est: 5.06B (+35.1%)
|
3.11B
est: 5.39B (-42.2%)
|
4.58B
est: -3.03B (+250.7%)
|
7.81B
est: -3.37B (+331.4%)
|
8.38B
est: -3.56B (+335.6%)
|
8.18B
est: 7.80B (+4.9%)
|
12.61B
est: 9.27B (+36.1%)
|
9.49B
9.39B – 9.58B
+2.4% YoY
|
10.41B
10.35B – 10.46B
+9.7% YoY
|
11.51B
11.39B – 11.61B
+10.6% YoY
|
| Net Income |
3.81B
est: 5.23B (-27.2%)
|
3.76B
est: 4.05B (-7.2%)
|
3.37B
est: 3.95B (-14.7%)
|
3.51B
est: 3.52B (-0.4%)
|
4.45B
est: 3.72B (+19.9%)
|
932.05M
est: 4.47B (-79.2%)
|
3.58B
est: 938.65M (+281.6%)
|
16.95B
est: 1.04B (+1,523.8%)
|
6.11B
est: 1.10B (+455.1%)
|
5.90B
est: 6.77B (-12.9%)
|
9.28B
est: 8.97B (+3.4%)
|
10.47B
10.20B – 10.64B
+16.8% YoY
|
11.77B
11.46B – 12.17B
+12.4% YoY
|
13.41B
12.88B – 13.88B
+14.0% YoY
|
| SGA |
5.23B
est: 5.91B (-11.4%)
|
5.60B
est: 8.70B (-35.6%)
|
6.03B
est: 8.57B (-29.6%)
|
6.40B
est: 9.19B (-30.4%)
|
6.93B
est: 9.90B (-30.0%)
|
7.74B
est: 9.79B (-20.9%)
|
6.86B
est: 10.67B (-35.7%)
|
7.40B
est: 11.87B (-37.7%)
|
7.06B
est: 12.51B (-43.6%)
|
7.36B
est: 7.24B (+1.6%)
|
7.02B
est: 8.15B (-13.9%)
|
8.34B
8.26B – 8.42B
+2.4% YoY
|
9.15B
9.10B – 9.19B
+9.7% YoY
|
10.12B
10.01B – 10.21B
+10.6% YoY
|
| EPS |
21.89
est: 30.88 (-29.1%)
|
22.20
est: 26.89 (-17.4%)
|
19.88
est: 19.31 (+3.0%)
|
20.70
est: 21.07 (-1.8%)
|
26.29
est: 24.69 (+6.5%)
|
5.50
est: 23.70 (-76.8%)
|
21.14
est: 32.21 (-34.4%)
|
100.04
est: 37.86 (+164.3%)
|
35.87
est: 38.13 (-5.9%)
|
34.83
est: 39.90 (-12.7%)
|
54.76
est: 52.93 (+3.5%)
|
61.80
60.20 – 62.80
+16.8% YoY
|
69.45
67.68 – 71.83
+12.4% YoY
|
79.18
76.04 – 81.95
+14.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
609.91M
OE per share TTM
3.60
Owner's Yield
0.15%
Maintenance CapEx ratio
0.77%
Maint CapEx / Avg PPE
16.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 24 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Emerging Markets Ex-China ETF VEXC | 0.01% | 30.0K | 0.07% |
| 2 | Schwab Emerging Markets Equity ETF SCHE | 0.01% | 1.28M | 0.06% |
| 3 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.01% | 558.0K | 0.17% |
| 4 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.01% | 558.0K | 0.17% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.01% | 120.4K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.01% | 271.7K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.01% | 13.41M | 0.06% |
| 8 | Vanguard FTSE Asia ex Japan Shares Index ETF VAE.AX | 0.01% | 45.5K | 0.40% |
| 9 | Vanguard ESG International Stock ETF VSGX | 0.00% | 172.8K | 0.10% |
| 10 | Vanguard All-World ex-US Shares Index ETF VEU.AX | 0.00% | 104.5K | 0.04% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
3.87M
Shares Outstanding
169.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bhushan Akshikar | MD & Executive Director | 64M | male |
| Ronojit Biswas | Whole-Time Director & Chief Financial Officer | 60M | male |
| Aparajita Rajput | Vice President of Technology | — | female |
| Carson Dalton | Executive Vice President of Communications & Government Affairs | — | male |
| Harsh V. Trehan | Executive Vice President of Human Resources | — | male |
| Rishikesh S. Jaiwant | Executive Vice President of Supply Chain Operations | — | male |
| Shalini Menon | Executive Vice President of Medical Affairs | — | — |
| Simrat Sohal | Vice President of Ethics & Compliance | — | female |
| Ajay Avinash Nadkarni | Vice President of Administration & Real Estate and Company Secretary | — | male |
| Sukanya Choudhary | Executive Vice President of Regulatory Affairs | — | female |
| Amit G. Pandey | Executive Vice President of Legal | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GLAXO.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
